Skip to main content
MTRI logo

Mentari Therapeutics, Inc. (MTRI)

MTRINASDAQHealthcareBiotechnology

-Today:- (-)

Loading latest quote…

Market cap
-
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
-
Volume (live)
-
Avg. volume (3M)
-

Mentari Therapeutics (MTRI) Income Statement

In Q1 fiscal 2026 (quarter ended Mar 31, 2026), Mentari Therapeutics posted a net loss of $18.21M.

Mentari Therapeutics Income Statement Analysis

Values in dollars

Scroll to see more
Mentari Therapeutics, Inc. income statement - Annual data in dollars
Breakdown
Period ending
Revenue & Gross Profit
Revenue
Cost of Revenue
Gross Profit
Operating Expenses
Research & Development
Selling, General & Administrative
Operating Expenses
Operating Income
Other Income/Expense
Interest Income
Interest Expense
Other Income/Expense
Income
Income Before Tax
Income Tax Expense
Net Income
Net Income - Continuous Operations
Net Income - Discontinued Operations
EBITDA
EBIT
Depreciation & Amortization
Earnings Per Share
Basic EPS
Diluted EPS
Basic Shares Outstanding
Diluted Shares Outstanding

Source: Company financial statements from annual and quarterly filings. Data as of Mar 31, 2026. Data sources and methodology

Frequently Asked Questions About Mentari Therapeutics Financial Statements

Is Mentari Therapeutics profitable?

No. Mentari Therapeutics reported a net loss of $18.21M in Q1 fiscal 2026.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition